Education and Training
Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
RATIONALE: Lenalidomide may stop the growth of mycosis fungoides/Sezary syndrome by blocking blood flow to the cancer.
PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with relapsed mycosis fungoides/Sezary syndrome.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: lenalidomide
Eligibility
DISEASE CHARACTERISTICS:
- Histologically confirmed mycosis fungoides/Sézary syndrome
- Stage IA-IVB disease
- Must have failed ≥ 1 prior topical treatment, including any of the following:
- Steroids
- Nitrogen mustard
- Retinoids
- Phototherapy
- Photochemotherapy
- Radiotherapy
- Total skin electron beam
- Measurable disease with ≥ 1 indicator lesion designated prior to study entry
- Erythrodermic patients are eligible
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- WBC ≥ 3,000/mm³
- ANC ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Creatinine ≤ 2.0 mg/dL
- Bilirubin ≤ 2.2 mg/dL
- AST and ALT ≤ 2 times upper limit of normal
- Not pregnant or nursing
- Negative pregnancy test
- Fertile women must use effective double-method contraception for ≥ 4 weeks before,
during, and for ≥ 4 weeks after completion of study therapy
- Fertile men must use effective contraception during and for ≥ 4 weeks after completion
of study therapy
- No other malignancy within the past 5 years except treated squamous cell and basal
cell carcinoma of the skin, carcinoma in situ of the cervix, or surgically removed
melanoma in situ of the skin (stage 0), with histologically confirmed free margins of
excision and no current evidence of disease
- No acute infection requiring systemic treatment
- No known allergic reaction or hypersensitivity to thalidomide
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 4 weeks since prior topical therapy, systemic chemotherapy, or biological
therapy
- No prior stem cell transplantation
- No other concurrent systemic antipsoriatic or anticancer therapies, including
radiotherapy, thalidomide, or other investigational agents
- No other concurrent topical agents except emollients
Ages Eligible for Study
18 Years - 120 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Natalie Viakhireva
6507238949
Not Recruiting